KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sarepta Therapeutics (SRPT) Equity Ratio (2016 - 2025)

Historic Equity Ratio for Sarepta Therapeutics (SRPT) over the last 15 years, with Q3 2025 value amounting to 0.38.

  • Sarepta Therapeutics' Equity Ratio rose 1140.74% to 0.38 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.38, marking a year-over-year increase of 1140.74%. This contributed to the annual value of 0.39 for FY2024, which is 4644.36% up from last year.
  • According to the latest figures from Q3 2025, Sarepta Therapeutics' Equity Ratio is 0.38, which was up 1140.74% from 0.37 recorded in Q2 2025.
  • Sarepta Therapeutics' 5-year Equity Ratio high stood at 0.39 for Q4 2024, and its period low was 0.12 during Q4 2022.
  • For the 5-year period, Sarepta Therapeutics' Equity Ratio averaged around 0.26, with its median value being 0.26 (2023).
  • Per our database at Business Quant, Sarepta Therapeutics' Equity Ratio crashed by 5825.87% in 2022 and then skyrocketed by 11391.93% in 2023.
  • Quarter analysis of 5 years shows Sarepta Therapeutics' Equity Ratio stood at 0.29 in 2021, then tumbled by 58.26% to 0.12 in 2022, then soared by 113.92% to 0.26 in 2023, then skyrocketed by 46.44% to 0.39 in 2024, then fell by 1.97% to 0.38 in 2025.
  • Its last three reported values are 0.38 in Q3 2025, 0.37 for Q2 2025, and 0.33 during Q1 2025.